Inspire Investing LLC Has $1.62 Million Holdings in Globus Medical, Inc. $GMED

Inspire Investing LLC raised its position in shares of Globus Medical, Inc. (NYSE:GMED) by 234,962.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 18,805 shares of the medical device company’s stock after acquiring an additional 18,797 shares during the period. Inspire Investing LLC’s holdings in Globus Medical were worth $1,620,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. SBI Securities Co. Ltd. raised its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the last quarter. Advisory Services Network LLC acquired a new position in Globus Medical in the third quarter worth $26,000. EverSource Wealth Advisors LLC grew its holdings in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Globus Medical by 83.4% during the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after purchasing an additional 242 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Activity

In other news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 18.38% of the company’s stock.

Globus Medical Stock Performance

Shares of Globus Medical stock opened at $79.16 on Wednesday. The firm has a fifty day moving average of $83.07 and a two-hundred day moving average of $87.31. The stock has a market capitalization of $10.74 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 1.73 and a beta of 0.95. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GMED shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Needham & Company LLC raised their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Wells Fargo & Company decreased their price target on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $105.00.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.